BioCardia Inc (OTCMKTS:BCDA) a leader in the advancement of comprehensive offerings for cardiovascular regenerative treatments reported the commencement of the “CardiAMP” Heart Failure pivotal study, a controlled, randomized, multi-center trial of up to 260 subjects assessing CardiAMP cell treatment at up to 40 clinical locations in the United States.
The study has been commenced at two world-class centers. The first center is Johns Hopkins University, where the study will be started under the direction of Dr. Gary Gerstenblith and Dr. Peter Johnston. Second center for trial is the University of Florida at Gainesville, where the trial will be carried out under the direction of Dr. Carl Pepine and Dr. David Anderson.
The management speaks
Eric Duckers, MD, the Chief Medical Officer of BioCardia, reported that they are delighted to be working with the prominent clinical research teams at these important centers to support a therapeutic plan that has immense promise to assist patients suffering from heart failure seen after a heart attack.
The CardiAMP treatment for heart failure incorporates a biomarker panel, a cell processing plan for autologous bone marrow-derived cells, and an innovative transendocardial delivery system. This treatment will be assessment under the PMA regulations by the FDA’s CBER division.
BioCardia, Inc., sited in San Carlos, is advancing regenerative biologic therapies to cure cardiovascular disease. CardiALLO® and CardiAMP® cell therapies are the firm’s biotherapeutic product contenders in clinical advancement. The firm’s current products comprise the Helix™ transendocardial delivery plan and the Morph® portfolio.
BioCardia even associates with other biotherapeutic firms to offer its Helix systems and clinical sustenance to their plans studying therapies for the cure of heart failure, acute myocardial infarction and chronic myocardial ischemia.
In the other trading session, the stock price of BioCardia jumped over 22% to close the day at $1.03. The gains came at a share volume of 3.10 million compared to average share volume of 674,551.